



KINECT-HD

A Clinical Research Study to Assess the Safety, Tolerability, and Effectiveness of Valbenazine for the Treatment of Chorea Associated with Huntington Disease (HD)

This is a clinical research study for people diagnosed with Huntington disease. It is roughly an 18 week long study being conducted to determine the safety, tolerability, and effectiveness of valbenazine for the treatment of chorea associated with Huntington disease. The use of valbenazine for the treatment of chorea associated with Huntington disease has not been approved by the US Food and Drug Administration (FDA).

INTERESTED?

Contact Raymond James at 617-638-7745, or rcjames@bu.edu.

ARE YOU ELIGIBLE?

- Ages 18-75 years and have a diagnosis of motor manifest HD.
- Able to commit to study visits every two weeks during the 18-week study.
- Be able to read and understand English.
- Be able to walk with or without the assistance of a person.
- Subjects of childbearing potential who do not practice total abstinence must agree to use hormonal or non-hormonal contraception consistently during the screening, treatment and follow-up periods of the study.

ABOUT THE STUDY.

- This study is roughly 18 weeks long and includes a screening period, a study drug dose-adjustment period, a maintenance period, and a follow-up period.
- Participants in this study will undergo dosing of study drug or placebo, blood draws, and various cognitive and motor examinations during the study visits.
- Participants will be compensated for each study visit completed.